Fortrea Holdings Inc.今日正式宣布，将收购Worldwide Clinical Trials的临床药理学部门以及生物分析实验室运营业务。这一战略举措标志着Fortrea在临床研究服务领域的布局再度深化，旨在扩大其早期药物开发能力，并巩固其在生物分析服务方面的市场地位。此次交易的具体财务条款尚未对外披露，但业界普遍预期此举将助力Fortrea进一步拓展客户基础，增强一体化服务链条，从而在全球临床试验服务市场中占据更有利的竞争位置。
Fortrea Holdings Inc.今日正式宣布，将收购Worldwide Clinical Trials的临床药理学部门以及生物分析实验室运营业务。这一战略举措标志着Fortrea在临床研究服务领域的布局再度深化，旨在扩大其早期药物开发能力，并巩固其在生物分析服务方面的市场地位。此次交易的具体财务条款尚未对外披露，但业界普遍预期此举将助力Fortrea进一步拓展客户基础，增强一体化服务链条，从而在全球临床试验服务市场中占据更有利的竞争位置。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.